纤维化:从机制到药物
Neil C Henderson1,2, Florian Rieder3,4, Thomas A Wynn5
1University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh BioQuarter, Edinburgh, UK.
Nature
|November 26, 2020
概括
纤维化是主要的死亡原因, 研究正在探索通过向关键机制来治疗纤维化疾病的新疗法.
科学领域:
- 病理生物学
- 翻译医学
- 复原医学
背景情况:
- 纤维化会影响任何器官, 导致发达国家的45%的死亡.
- 以前被认为是渐进且不可逆转的纤维化现在被理解为一个动态的过程.
- 在确定抗纤维素点和开发有效的人类治疗之间存在很大的差距.
研究的目的:
- 讨论剖析纤维化机制的实验策略.
- 探索纤维化治疗的转化方法.
- 突显纤维性疾病的精准医学的出现.
主要方法:
- 对各种器官系统的临床前模型和临床试验的审查.
- 对调节纤维化的细胞和分子机制的分析.
- 对治疗发展的转化策略的研究.
主要成果:
- 纤维化是一个动态和潜在的可逆过程, 挑战以前的假设.
- 实验策略正在揭示纤维化的关键细胞和分子调节剂.
- 转化方法正在为纤维化治疗准确医学铺平道路.
结论:
- 纤维化是一种具有治疗潜力的动态过程.
- 了解纤维化病理生物学对于开发新疗法至关重要.
- 精确医学为治疗纤维化疾病提供了前景.
相关概念视频
Cystic Fibrosis: Management
318
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
318
Introduction to Fibroblasts
3.6K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.6K
Ultrasound II: Endoscopic Ultrasound and FibroScan
332
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
332
Inflammatory Bowel Disease IV: Pharmacological Management
311
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
311
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
318
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
318
Drugs for Treatment of Constipation-Predominant IBS
524
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
524


